<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Members of the Childrens <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Study Group treated 234 eligible patients in a randomized trial designed to study the relative effectiveness of two therapy programs for the treatment of childhood and adolescent non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Two chemotherapeutic strategies were compared: a 4-drug regimen (COMP) and a 10-drug regimen (modified LSA2-L2) </plain></SENT>
<SENT sid="2" pm="."><plain>Failure-free survival for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 60 per cent at 24 months </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with disseminated disease treatment success was influenced by both the histologic subtype of disease and the therapeutic regimen followed </plain></SENT>
<SENT sid="4" pm="."><plain>The 10-drug program was more effective than the 4-drug program in patients with disseminated lymphoblastic disease (two-year failure-free survival rate, 76 vs. 26 per cent, respectively; P = 0.0002), whereas the 4-drug program was more effective than the 10-drug program in those with nonlymphoblastic disease (57 vs. 28 per cent, respectively, P = 0.008) </plain></SENT>
<SENT sid="5" pm="."><plain>The less toxic, more easily administered 4-drug regimen was as effective as the 10-drug regimen in patients with <z:e sem="disease" ids="C0277565" disease_type="Disease or Syndrome" abbrv="">localized disease</z:e> (89 vs. 84 per cent, respectively) </plain></SENT>
</text></document>